CD8A and neoplasm: Consistent with this premise, we show that ATRi reduces the existing proliferating T cell pool in both the tumor and DLN and that, with the appropriate sequence and combination treatment, this generates a niche in which new, tumor-reactive CD8+ T cells can expand.